# Anti-PD-1 Antibody Combined With Peg-Asparaginase and Chidamide for the Early Stage of NK/T Cell Lymphoma

> **NCT04414969** · PHASE2 · UNKNOWN · sponsor: **Hunan Cancer Hospital** · enrollment: 35 (estimated)

## Conditions studied

- Immune Checkpoint Inhibitor
- Chemotherapy Effect
- Epigenetic Disorder
- NK/T-cell Lymphoma of Nasal Cavity

## Interventions

- **DRUG:** Anti-PD-1 antibody+Peg-Asparaginase+Chidamide

## Key facts

- **NCT ID:** NCT04414969
- **Lead sponsor:** Hunan Cancer Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-06-26
- **Primary completion:** 2022-07-01
- **Final completion:** 2025-07-01
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2020-07-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04414969

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04414969, "Anti-PD-1 Antibody Combined With Peg-Asparaginase and Chidamide for the Early Stage of NK/T Cell Lymphoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04414969. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*